WO2005032593A1 - 核移行能を有するポリアルギニン修飾リポソーム - Google Patents
核移行能を有するポリアルギニン修飾リポソーム Download PDFInfo
- Publication number
- WO2005032593A1 WO2005032593A1 PCT/JP2004/014500 JP2004014500W WO2005032593A1 WO 2005032593 A1 WO2005032593 A1 WO 2005032593A1 JP 2004014500 W JP2004014500 W JP 2004014500W WO 2005032593 A1 WO2005032593 A1 WO 2005032593A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ribosome
- peptide
- cells
- lipid
- target substance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
Definitions
- the types of lipids constituting the lipid bilayer are not particularly limited. Specific examples thereof include phosphatidylcholines (eg, dioleoylphosphatidylcholine, dilauroylphosphatidylcholine, dimyristoylphosphatidylcholine).
- phosphatidylcholines eg, dioleoylphosphatidylcholine, dilauroylphosphatidylcholine, dimyristoylphosphatidylcholine.
- Hydrogenated products sphingomyelin, ganglioside, etc.
- glycolipids Ru can be used one or two or more of these.
- the phospholipid may be any of natural lipids derived from egg yolk, soybean and other animals and plants (eg, egg yolk lecithin, soybean lecithin, etc.), synthetic lipids and semi-synthetic lipids.
- the lipid membrane is hydrated and stirred or subjected to ultrasonic treatment to produce a liposome having the peptide on the surface.
- the organic solvent is evaporated off to obtain a lipid membrane.
- the lipid membrane is hydrated, and ribosomes are produced by stirring or ultrasonication. I do.
- the peptide can be introduced to the surface of the ribosome by adding the peptide modified with a hydrophobic group or a hydrophobic compound to the external solution of the ribosome.
- the amount of the peptide present on the surface of the ribosome of the present invention is at least 2% (molar ratio), preferably at least 3% (molar ratio), more preferably at least 4%, based on the total lipids constituting the lipid bilayer. (Molar ratio) or more, the ribosome of the present invention can effectively exhibit intracellular translocation and nuclear translocation at a low temperature (usually 410 ° C, preferably 416 ° C). it can.
- the upper limit of the amount of the peptide is usually 30% (molar ratio), preferably 25% (molar ratio), more preferably 20% (molar ratio) based on the total lipid constituting the lipid bilayer. .
- the obtained lipid membrane (10 mol) was hydrated using 1 mL of phosphate buffered saline pre-warmed to 50 ° C. and stirred for 5 seconds.
- the lipid dispersion was passed through a 400 nm, 200 nm or 100 nm polycarbonate membrane filter 11 times each. This resulted in the formation of ribosomes having octaarginine (5 mol% of total lipids) on the surface.
- NIH3T3 cells coexist with metabolic inhibitors (0.1% sodium azide, 10mM sodium fluoride and 1gZmL antimycin A) or sucrose (0.4M), an endocytosis inhibitor After incubation at 37 ° C for 30 minutes at 37 ° C for 10 minutes, or at 37 ° C for 10 minutes in the presence of the macropinocytosis inhibitor Amiloride (5 mM), or at 4 ° C for 30 minutes in the absence of the inhibitor Then, ribosome (octaarginine content: 0.8 mol% or 5 mol% of the total lipid) in which octaarginine was introduced to the surface and the rhodamine dye was encapsulated in the inner aqueous phase was added, and the mixture was incubated for 1 hour.
- metabolic inhibitors 0.1% sodium azide, 10mM sodium fluoride and 1gZmL antimycin A
- sucrose 0.4M
- an endocytosis inhibitor After incubation at 37 ° C for 30
- FIG. 4 is a view showing the results of comparing the intracellular region areas where fluorescence is observed under various conditions.
- FIG. 5 shows the results of measuring luciferase expression activity under various conditions.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005514470A JP4628955B2 (ja) | 2003-10-01 | 2004-10-01 | 核移行能を有するポリアルギニン修飾リポソーム |
EP04791967.5A EP1676588B1 (en) | 2003-10-01 | 2004-10-01 | Polyarginine-modified liposome having nuclear entry ability |
CA2540917A CA2540917C (en) | 2003-10-01 | 2004-10-01 | Polyarginine-modified liposome having nuclear entry ability |
CN2004800281353A CN1863558B (zh) | 2003-10-01 | 2004-10-01 | 具有向核内转移能力的聚精氨酸修饰的脂质体 |
KR1020067004866A KR101097729B1 (ko) | 2003-10-01 | 2006-03-09 | 핵 이행 기능을 갖는 폴리아르기닌 수식 리포좀 |
US11/396,081 US8592210B2 (en) | 2003-10-01 | 2006-03-31 | Polyarginine-modified liposome having nuclear entry ability |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003343857 | 2003-10-01 | ||
JP2003-343857 | 2003-10-01 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/396,081 Continuation US8592210B2 (en) | 2003-10-01 | 2006-03-31 | Polyarginine-modified liposome having nuclear entry ability |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005032593A1 true WO2005032593A1 (ja) | 2005-04-14 |
Family
ID=34419361
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/014500 WO2005032593A1 (ja) | 2003-10-01 | 2004-10-01 | 核移行能を有するポリアルギニン修飾リポソーム |
Country Status (7)
Country | Link |
---|---|
US (1) | US8592210B2 (ja) |
EP (1) | EP1676588B1 (ja) |
JP (1) | JP4628955B2 (ja) |
KR (1) | KR101097729B1 (ja) |
CN (1) | CN1863558B (ja) |
CA (1) | CA2540917C (ja) |
WO (1) | WO2005032593A1 (ja) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006095837A1 (ja) * | 2005-03-09 | 2006-09-14 | National University Corporation Hokkaido University | 目的物質をミトコンドリア内に送達可能な脂質膜構造体 |
JP2007166946A (ja) * | 2005-12-20 | 2007-07-05 | Hokkaido Univ | 標的遺伝子の発現を抑制するための組成物 |
WO2007102481A1 (ja) * | 2006-03-07 | 2007-09-13 | National University Corporation Hokkaido University | 目的物質の核内送達用ベクター |
WO2007132790A1 (ja) * | 2006-05-12 | 2007-11-22 | National University Corporation Hokkaido University | 細菌菌体成分を含む脂質膜を有するリポソーム |
EP1867726A1 (en) * | 2005-03-24 | 2007-12-19 | National University Corporation Hokkaido University | Liposome capable of effective delivery of given substance into nucleus |
WO2008068982A1 (ja) * | 2006-12-08 | 2008-06-12 | Osaka University | 細胞内移行ペプチドを有効成分とする遺伝子導入補助剤および該遺伝子導入補助剤を利用した遺伝子導入方法 |
WO2008105174A1 (ja) | 2007-02-28 | 2008-09-04 | National University Corporation Hokkaido University | 細胞性免疫誘導用リポソーム |
WO2008105178A1 (ja) | 2007-02-28 | 2008-09-04 | National University Corporation Hokkaido University | リポソーム用生体成分抵抗性増強剤及びこれにより修飾されたリポソーム |
WO2010110471A1 (ja) * | 2009-03-23 | 2010-09-30 | 国立大学法人北海道大学 | 脂質膜構造体 |
WO2011132713A1 (ja) | 2010-04-21 | 2011-10-27 | 国立大学法人北海道大学 | 核内移行性を有する脂質膜構造体 |
WO2011135905A1 (ja) * | 2010-04-28 | 2011-11-03 | 国立大学法人北海道大学 | 脂質膜構造体 |
US8143413B2 (en) | 2008-09-02 | 2012-03-27 | Eisai R&D Management Co., Ltd. | Polycationized phospholipid derivatives |
WO2013073480A1 (ja) | 2011-11-18 | 2013-05-23 | 日油株式会社 | 細胞内動態を改善したカチオン性脂質 |
WO2014034669A1 (ja) | 2012-08-28 | 2014-03-06 | 国立大学法人北海道大学 | 非極性溶媒に分散性を有する細菌菌体成分を内封する脂質膜構造体およびその製造方法 |
JP2015081228A (ja) * | 2013-10-21 | 2015-04-27 | 学校法人東京薬科大学 | 負電荷バブルリポソーム及びカチオン性ペプチドからなる薬物送達キャリア |
CN105396121A (zh) * | 2015-11-20 | 2016-03-16 | 钟志容 | Gx1修饰的阴离子脂质体腺病毒载体及其制备方法与应用 |
WO2018230710A1 (ja) | 2017-06-15 | 2018-12-20 | 国立大学法人北海道大学 | siRNA細胞内送達のための脂質膜構造体 |
US10182987B2 (en) | 2014-05-20 | 2019-01-22 | National University Corporation Hokkaido University | Lipid membrane structure for intracellular delivery of siRNA |
WO2020241679A1 (ja) | 2019-05-30 | 2020-12-03 | 国立大学法人北海道大学 | 脂質ナノ粒子 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2044132A1 (en) * | 2006-07-12 | 2009-04-08 | The Robert Gordon University | Composition |
WO2009078820A1 (en) * | 2007-12-18 | 2009-06-25 | Agency For Science, Technology And Research | Cationic core-shell peptide nanoparticles |
CN102526742B (zh) * | 2012-03-05 | 2013-07-10 | 中国药科大学 | 具有溶酶体逃逸能力的功能性纳米载体及其制备方法 |
KR101835554B1 (ko) | 2014-06-24 | 2018-04-19 | 서울대학교 산학협력단 | C/ebp를 포함하는 유도성 t 조절세포 분화촉진 또는 안정화 조성물 및 방법 |
WO2016014908A1 (en) | 2014-07-25 | 2016-01-28 | Academia Sinica | Bipartite molecules and uses thereof in treating diseases associated with abnormal protein aggregates |
CN105801668B (zh) * | 2016-04-01 | 2020-08-07 | 天津大学 | 一种寡聚精氨酸修饰的磷脂与其组装的纳米粒及制备方法和应用 |
ES2664584B2 (es) | 2016-09-19 | 2018-12-13 | Universidade De Santiago De Compostela | Nanoparticulas con interiores protegidos, y métodos de uso de las mismas |
CN114010801B (zh) * | 2021-11-16 | 2023-09-26 | 上海理工大学 | 一种l-抗坏血酸棕榈酸酯修饰的小分子肽脂质体及其制备与应用 |
CN116983268B (zh) * | 2023-08-04 | 2024-04-30 | 清华大学 | 一种用于药物靶向递送的多肽修饰的脂质体及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001080900A2 (en) * | 2000-04-20 | 2001-11-01 | The University Of British Columbia | Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane |
JP2003514843A (ja) * | 1999-11-24 | 2003-04-22 | ザ リポソーム カンパニー、インコーポレーテッド | モジュラー標的化リポソーム送達システム |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9014221D0 (en) * | 1990-06-26 | 1990-08-15 | Janssen Pharmaceutica Nv | Method of treating alopecia |
ATE273320T1 (de) * | 1996-04-11 | 2004-08-15 | Univ British Columbia | Fusogene liposomen |
US6372720B1 (en) * | 1998-02-05 | 2002-04-16 | Kenneth J. Longmuir | Liposome fusion and delivery vehicle |
US20030072794A1 (en) * | 2000-06-09 | 2003-04-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
GB0100196D0 (en) * | 2001-01-04 | 2001-02-14 | Anmat Technology Ltd | Peptides |
-
2004
- 2004-10-01 JP JP2005514470A patent/JP4628955B2/ja not_active Expired - Fee Related
- 2004-10-01 CN CN2004800281353A patent/CN1863558B/zh not_active Expired - Fee Related
- 2004-10-01 EP EP04791967.5A patent/EP1676588B1/en not_active Not-in-force
- 2004-10-01 CA CA2540917A patent/CA2540917C/en not_active Expired - Fee Related
- 2004-10-01 WO PCT/JP2004/014500 patent/WO2005032593A1/ja active Search and Examination
-
2006
- 2006-03-09 KR KR1020067004866A patent/KR101097729B1/ko not_active IP Right Cessation
- 2006-03-31 US US11/396,081 patent/US8592210B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003514843A (ja) * | 1999-11-24 | 2003-04-22 | ザ リポソーム カンパニー、インコーポレーテッド | モジュラー標的化リポソーム送達システム |
WO2001080900A2 (en) * | 2000-04-20 | 2001-11-01 | The University Of British Columbia | Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane |
Non-Patent Citations (4)
Title |
---|
BONDESON, J. ET AL.: "Promotion of acid-induced membrane fusion by basic peptides. Amino acid and phospholipid specificities", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1026, 1990, pages 186 - 194, XP023798039 * |
FUTAKI, S. ET AL.: "Arginine-rich Peptides", J. BIOL. CHEM., vol. 276, no. 8, 2001, pages 5836 - 5840, XP002210171 * |
See also references of EP1676588A4 * |
SUZUKI, T. ET AL.: "Possible Existence of Common Internalization Mechanisms among Arginine-rich Peptides", J. BIOL. CHEM., vol. 277, no. 4, 2002, pages 2437 - 2443, XP002963938 * |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006095837A1 (ja) * | 2005-03-09 | 2006-09-14 | National University Corporation Hokkaido University | 目的物質をミトコンドリア内に送達可能な脂質膜構造体 |
JP5067733B2 (ja) * | 2005-03-09 | 2012-11-07 | 国立大学法人北海道大学 | 目的物質をミトコンドリア内に送達可能な脂質膜構造体 |
EP1867726A1 (en) * | 2005-03-24 | 2007-12-19 | National University Corporation Hokkaido University | Liposome capable of effective delivery of given substance into nucleus |
EP1867726A4 (en) * | 2005-03-24 | 2008-09-24 | Univ Hokkaido Nat Univ Corp | FOR THE EFFECTIVE DELIVERY OF A GIVEN SUBSTANCE IN THE CORE CORE CAPABLE LIPOSOME |
JP2007166946A (ja) * | 2005-12-20 | 2007-07-05 | Hokkaido Univ | 標的遺伝子の発現を抑制するための組成物 |
WO2007102481A1 (ja) * | 2006-03-07 | 2007-09-13 | National University Corporation Hokkaido University | 目的物質の核内送達用ベクター |
WO2007132790A1 (ja) * | 2006-05-12 | 2007-11-22 | National University Corporation Hokkaido University | 細菌菌体成分を含む脂質膜を有するリポソーム |
JPWO2007132790A1 (ja) * | 2006-05-12 | 2009-09-24 | 国立大学法人 北海道大学 | 細菌菌体成分を含む脂質膜を有するリポソーム |
WO2008068982A1 (ja) * | 2006-12-08 | 2008-06-12 | Osaka University | 細胞内移行ペプチドを有効成分とする遺伝子導入補助剤および該遺伝子導入補助剤を利用した遺伝子導入方法 |
WO2008105174A1 (ja) | 2007-02-28 | 2008-09-04 | National University Corporation Hokkaido University | 細胞性免疫誘導用リポソーム |
WO2008105178A1 (ja) | 2007-02-28 | 2008-09-04 | National University Corporation Hokkaido University | リポソーム用生体成分抵抗性増強剤及びこれにより修飾されたリポソーム |
JPWO2008105174A1 (ja) * | 2007-02-28 | 2010-06-03 | 国立大学法人北海道大学 | 細胞性免疫誘導用リポソーム |
US8143413B2 (en) | 2008-09-02 | 2012-03-27 | Eisai R&D Management Co., Ltd. | Polycationized phospholipid derivatives |
WO2010110471A1 (ja) * | 2009-03-23 | 2010-09-30 | 国立大学法人北海道大学 | 脂質膜構造体 |
JP5794541B2 (ja) * | 2010-04-21 | 2015-10-14 | 国立大学法人北海道大学 | 核内移行性を有する脂質膜構造体 |
WO2011132713A1 (ja) | 2010-04-21 | 2011-10-27 | 国立大学法人北海道大学 | 核内移行性を有する脂質膜構造体 |
US8981044B2 (en) | 2010-04-21 | 2015-03-17 | National University Corporation Hokkaido University | Lipid membrane structure having intranuclear migrating property |
WO2011135905A1 (ja) * | 2010-04-28 | 2011-11-03 | 国立大学法人北海道大学 | 脂質膜構造体 |
JP5787323B2 (ja) * | 2010-04-28 | 2015-09-30 | 国立大学法人北海道大学 | 脂質膜構造体 |
WO2013073480A1 (ja) | 2011-11-18 | 2013-05-23 | 日油株式会社 | 細胞内動態を改善したカチオン性脂質 |
WO2014034669A1 (ja) | 2012-08-28 | 2014-03-06 | 国立大学法人北海道大学 | 非極性溶媒に分散性を有する細菌菌体成分を内封する脂質膜構造体およびその製造方法 |
JP2015081228A (ja) * | 2013-10-21 | 2015-04-27 | 学校法人東京薬科大学 | 負電荷バブルリポソーム及びカチオン性ペプチドからなる薬物送達キャリア |
US10182987B2 (en) | 2014-05-20 | 2019-01-22 | National University Corporation Hokkaido University | Lipid membrane structure for intracellular delivery of siRNA |
CN105396121A (zh) * | 2015-11-20 | 2016-03-16 | 钟志容 | Gx1修饰的阴离子脂质体腺病毒载体及其制备方法与应用 |
WO2018230710A1 (ja) | 2017-06-15 | 2018-12-20 | 国立大学法人北海道大学 | siRNA細胞内送達のための脂質膜構造体 |
KR20200018782A (ko) | 2017-06-15 | 2020-02-20 | 국립대학법인 홋가이도 다이가쿠 | siRNA 세포 내 송달을 위한 지질막 구조체 |
US11517528B2 (en) | 2017-06-15 | 2022-12-06 | National University Corporation Hokkaido University | Lipid membrane structure for delivery into siRNA cell |
WO2020241679A1 (ja) | 2019-05-30 | 2020-12-03 | 国立大学法人北海道大学 | 脂質ナノ粒子 |
Also Published As
Publication number | Publication date |
---|---|
EP1676588A1 (en) | 2006-07-05 |
JP4628955B2 (ja) | 2011-02-09 |
KR101097729B1 (ko) | 2011-12-23 |
JPWO2005032593A1 (ja) | 2006-12-14 |
US20070059353A1 (en) | 2007-03-15 |
CA2540917A1 (en) | 2005-04-14 |
US8592210B2 (en) | 2013-11-26 |
EP1676588A4 (en) | 2009-12-02 |
EP1676588B1 (en) | 2013-12-11 |
CA2540917C (en) | 2012-03-27 |
CN1863558B (zh) | 2010-12-29 |
KR20060080926A (ko) | 2006-07-11 |
CN1863558A (zh) | 2006-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101097729B1 (ko) | 핵 이행 기능을 갖는 폴리아르기닌 수식 리포좀 | |
Amadio et al. | Nanosystems based on siRNA silencing HuR expression counteract diabetic retinopathy in rat | |
Koshkaryev et al. | Bleomycin in octaarginine-modified fusogenic liposomes results in improved tumor growth inhibition | |
Kibria et al. | Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery | |
Almofti et al. | Lipoplex size determines lipofection efficiency with or without serum | |
US20090305409A1 (en) | Liposome Capable of Effective Delivery of Given Substance Into Nucleus | |
CA2362485A1 (en) | Encapsulation of bioactive complexes in liposomes | |
Fonseca et al. | Targeting of sterically stabilised pH-sensitive liposomes to human T-leukaemia cells | |
Serikawa et al. | A new cationic liposome for efficient gene delivery with serum into cultured human cells: a quantitative analysis using two independent fluorescent probes | |
WO2007102481A1 (ja) | 目的物質の核内送達用ベクター | |
US20100166840A1 (en) | Liposome having lipid membrane containing bacterial cell component | |
US20100104623A1 (en) | Agent for enhancing the resistance of liposome against biological component, and liposome modified with the agent | |
Shao et al. | Intracellular drug delivery by sulfatide-mediated liposomes to gliomas | |
Hughes et al. | In vitro transport and delivery of antisense oligonucleotides | |
EP3936135A1 (en) | Nucleic acid delivery complex | |
US8097276B2 (en) | Method for coating particle with lipid film | |
Mozafari et al. | Prospects of anionic nanolipoplexes in nanotherapy: transmission electron microscopy and light scattering studies | |
Sasaki et al. | Construction of a multifunctional envelope-type nano device by a SUV*-fusion method | |
JP2006238839A (ja) | 核酸の細胞内送達効率又は細胞内発現効率を向上させた組成物 | |
JP2006167521A (ja) | Suv型リポソームの膜融合を利用した遺伝子等の新規封入技術 | |
JP2007166946A (ja) | 標的遺伝子の発現を抑制するための組成物 | |
Dini et al. | Interaction between isolated and purified liver cells and small unilamellar liposomes | |
WO2009131216A1 (ja) | オリゴアルキレングリコールで修飾された脂質膜構造体 | |
JP2014114267A (ja) | 脂質膜構造体に対して肝臓血管内皮細胞への移行能を付与および/または増強するペプチド、肝臓血管内皮細胞への移行能を有するまたは肝臓血管内皮細胞への移行能が増強された脂質膜構造体、ならびに脂質膜構造体に対して肝臓血管内皮細胞への移行能を付与および/または増強する剤 | |
Chan et al. | DNA–Lipid Amphiphiles for Drug and Gene Therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480028135.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020067004866 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2540917 Country of ref document: CA Ref document number: 2005514470 Country of ref document: JP Ref document number: 11396081 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004791967 Country of ref document: EP |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 2004791967 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067004866 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 11396081 Country of ref document: US |